Ask Warren

JONBUR Research · Initiation

Inventage Lab · 389470 · Biotech & Pharma

Inventage Lab: Persistent Losses, Cash Cushion and a Share Price Well Below Its 52-Week High

Why this report

Start of coverage: written when a reader opened this company and there was no report yet.

Inventage Lab is a KOSDAQ biotech with a market value of ₩334.0B, tiny revenue of ₩2.5B over the latest twelve months and a deep operating loss. The shares have fallen 31.3% in a year and sit 75.3% below the 52-week high of ₩101,700.

Written Oct 21, 2026 · Data as of Oct 20, 2026 · 0 views

This is not financial advice. The report does not recommend buying or selling anything.

XfWATGr/in@

Thesis

The data supports a picture of an early-stage company that spends far more than it earns. Trailing revenue is ₩2.5B against an operating loss of ₩33.6B, and free cash flow is negative ₩32.2B. Cash of ₩97.6B exceeds borrowings of ₩28.9B, which gives some room to keep funding operations.

What the data does not show is a clear path to profit. Revenue rose 64.8% in 2025, but the figures are small and have swung sharply from year to year. Net loss in the latest twelve months (₩3.1B) is much smaller than the operating loss, which suggests non-operating items had a large positive effect. The filings do not explain this in the data given.

News on October 14 and 15 mentions a US patent registration for a veterinary product and a sharp share price rise on the day of the second headline. Whether this leads to revenue is not available in the data. A conversion price adjustment on convertible preferred shares was filed on October 19.

Business overview

Inventage Lab (인벤티지랩) was founded on 2015-05-14 and listed on KOSDAQ on 2022-11-22. It is classified in Biotech & Pharma and has 13,307,708 listed shares. The CEO is listed as 김주희.

Revenue history is uneven: ₩3.7B in 2022, ₩658M in 2023 (down 82.3%), ₩1.8B in 2024 (up 170.9%) and ₩2.9B in 2025 (up 64.8%). The company has reported an operating loss in every year shown. Market value is far below large Korean biotech peers such as Samsung Biologics (₩64.4T) and Celltrion (₩45.8T).

Financial analysis

These figures come from filed financial statements. Over the twelve months to H1 2026, revenue was ₩2.5B, operating income was negative ₩33.6B and net income was negative ₩3.1B. Operating margin was -1359.7% and net margin was -127.0%. Return on equity was -5.2%.

Operating losses widened each year: ₩10.9B in 2022, ₩16.0B in 2023, ₩19.0B in 2024 and ₩28.4B in 2025. Net loss narrowed from ₩27.0B in 2023 to ₩8.5B in 2025, again pointing to non-operating gains. Annual ROE improved from -154.9% in 2023 to -17.4% in 2025.

The balance sheet shows liabilities at 74.8% of equity, cash of ₩97.6B and borrowings of ₩28.9B. Free cash flow was negative ₩32.2B over the period.

Valuation

With no profit, the price-to-earnings ratio and EV/EBITDA are not available. Price-to-book is 3.8, down from 17.4 at the end of 2025 and 8.7 at the end of 2024. Price-to-sales is 135.1 and enterprise value is ₩251.4B. Dividend yield is 0.0%.

Peers show price-to-book ratios of 2.6 (Celltrion), 2.7 (Yuhan), 5.7 (SK biopharmaceuticals), 7.7 (Samsung Biologics) and 30.0 (Alteogen), so Inventage Lab's 3.8 sits within that range. Peer price-to-earnings ratios of 14.6 to 83.3 cannot be compared, since Inventage Lab has no earnings.

The valuation model is a 5-year discounted cash flow at a 7.5% rate. It gives a model estimate based on the assumptions shown of ₩2,076 per share in the base case, with ₩2,501 for the bear case and ₩1,448 for the bull case. The bear and bull labels appear in the reverse order of their values, which is an inconsistency in the model output. All of these are far below the current price of ₩25,100. The gap suggests the market is pricing in much more than the model's cash flow assumptions, or that the model is weak for a company at this stage.

Catalysts

  • A US patent registration for a 12-month sustained veterinary castration agent was reported on October 14, with commercialization discussions mentioned.
  • A conversion price adjustment for convertible preferred shares was filed on October 19, which could affect share count dilution.
  • The half-year report filed on August 26 provides the latest financial figures, and the next periodic report will update them.
  • An investor relations event was held on September 15, and a stock purchase option grant was announced on July 24.
  • The company acquired its own convertible bonds before maturity in June, which may affect its debt and funding position.

Risks

  • Operating losses of ₩33.6B on revenue of ₩2.5B mean continued cash burn, with free cash flow at negative ₩32.2B.
  • Revenue has been volatile, including an 82.3% fall in 2023, so growth is not yet steady.
  • The share price is down 18.8% over three months and 31.3% over a year, showing high volatility.
  • Convertible instruments and stock options could dilute existing shareholders.
  • Over the last 20 days foreign investors sold ₩6.6B net and institutions sold ₩1.7B, while retail investors bought ₩8.4B, and foreign ownership slipped to 10.2% from 10.5%.

Closing view

The data shows a loss-making biotech with very small revenue, a sizeable cash balance and a share price that has fallen sharply from its high but still sits far above the model's per-share estimate. Recent patent news and a one-day price jump add interest, yet the filings and financials do not show how or when revenue could scale. Funding, dilution risk and the gap between price and model estimate are the main points to weigh. This report is not a recommendation.

Model estimate of fair value

Bear
₩2,501
-90%
Base
₩2,076
-91%
Bull
₩1,448
-94%

Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal.

Base case of the 5-year discounted cash flow model on the stock's Valuation tab (statements TTM to H1 2026; discount rate 7.5%). Bear and Bull move the main assumptions by fixed steps. See and change the assumptions

Filings and data used

Report history

  1. Oct 21, 2026InitiationStart of coverage (reader request)Inventage Lab: Persistent Losses, Cash Cushion and a Share Price Well Below Its 52-Week High

Built only from jonbur's own data: prices and investor flows, filed financial statements and filings, and news headlines. Disclosed (filed) data is labelled as such. Written by AI and may contain mistakes.

This is not financial advice. The report does not recommend buying or selling anything.

Source: KRX statistical information